Hepta Unveils First Multi-Omic Atlas of MASH, Linking Liver Pathway Biology to cfDNA Methylation in Blood
Hepta, a biotechnology company using transformer-based AI to decode the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease, today announced the creation of an unparalleled multi-omic atlas of metabolic dysfunction–associated steatohepatitis (MASH) in collaboration with Duke University. This work builds on Hepta’s expanded cfDNA studies with Mainz University and Akero Therapeutics’ Phase 3 clinical trial program, further strengthening the company’s partnerships across academic and clinical research.
Illumina and Grail Veterans Launch Hepta With First Liquid Biopsy-Native AI That Detects Liver Disease With Tissue-Level Biological Insights
Hepta, a biotechnology company using transformer-based AI to read the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease, today emerged from stealth with $6.7 million in seed funding led by Felicis Ventures and Illumina Ventures, with participation from SeaX Ventures, Alumni Ventures, and AME Cloud Ventures. The company also revealed clinical data showing its AI-powered epigenetics platform can identify patients with metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) with significant fibrosis with a diagnostic AUC of 0.86, cutting false positives threefold compared to standard blood tests.
